Bremen, September 30, 2015 - Yesterday's extraordinary general meeting of MeVis Medical Solutions AG resolved to approve the domination and profit and loss transfer agreement between the VMS Deutschland Holdings GmbH as the controlling company and MeVis Medical Solutions AG as the controlled company. The proposed resolution was approved by a majority of 98.40 % of all shareholders present or represented. In order to become effective, the domination and profit and loss transfer agreement requires registration with the commercial register.
Marcus Kirchhoff, CEO of MeVis Medical Solutions AG, pointed out: "The approval of the domination and profit and loss transfer agreement is an important milestone for the future of MeVis. It allows a close cooperation between MeVis and the Varian Group as well as the implementation of standardized organizational structures and strategies in this legal framework." Dr. Robert Hannemann, CFO of the Company, adds: "The contract also provides special protection measures for minority shareholders, such as the entitlement to receive an annual compensation of EUR 1.13 gross / EUR 0.95 net per share or the option to transfer MeVis shares to the VMS at a price of EUR 19.77."